Back to Stock Universe
Daily Decision Engine
CIPLA
Cipla Ltd. · Healthcare · Branded Medicines · Large Cap
HOLD with net score +0 (+2 buy, −2 sell). Strongest positive: P/B Below Its 5Y Median (weight 2). Caution: PEG Stretched (weight 2) flags risk.
Engine Verdict
Hold
Score
+0
Buy
+2
Sell
−2
Veto
—
Price Context
Current Price
₹1,440.10
1M
+2.92%
1Y
-4.15%
3Y
+13.33%
5Y
+8.66%
52W Low ₹1,165.70Now ₹1,440.1052W High ₹1,673.00
Price History (Yahoo) with Your Decisions
Returns Profile
VR Score Radar (out of 10)
Verdict Breakdown · 2 triggered / 21 active
P/B Below Its 5Y MedianBUYw2
P/B vs Median % < 0 → -12.67
PEG StretchedSELLw2
PEG > 2.5 → 2.54
VR Stock Rating StrongBUYw4
VR Stock Rating (1-5) ≥ 4 → 3.00
Failed: VR Stock Rating (1-5) = 3.00 is not ≥ 4.
P/E Below Its 5Y MedianBUYw2
P/E vs Median % < 0 → 3.82
Failed: P/E vs Median % = 3.82 is not < 0.
VR Valuation Score StrongBUYw2
VR Valuation Score (1-10) ≥ 6 → 5.00
Failed: VR Valuation Score (1-10) = 5.00 is not ≥ 6.
Cheap on EV/EBITDABUYw2
EV / EBITDA < 12 → 17.15
Failed: EV / EBITDA = 17.15 is not < 12.
VR Proprietary Scores
VR Stock Rating
3 / 5 ⭐
Quality
8/10
Growth
5/10
Valuation
5/10
Momentum
3/10
Fundamentals
P/E
30.18
vs 5Y median 29.07 · +3.8%
P/B
3.41
vs 5Y median 3.90 · -12.7%
EV/EBITDA
17.15
Price / CFO
29.71
Price / Sales
4.16
PEG
2.54
From VR
Earning Yield %
4.31
From VR
Dividend Yield %
0.90
FCF / Share
33.31
→ FCF Yield 2.31%
EPS
50.61
Market Cap
117056.79 Cr
Enterprise Value
107386.78 Cr
Engine Zone Timeline · 2 runs
06-250
06-260
STRONG BUY
BUY
HOLD
SELL
STRONG SELL
AVOID
Your Decisions on CIPLA · 0
No decisions logged on this stock yet.
Use “Log Decision” above to start your trade journal. Every decision will appear here with hindsight grade.
Position Lifecycle · CIPLA
No position taken yet
You've only WATCHED / SKIPPED so far. Log a BUY decision to begin the lifecycle.
Recent News · CIPLA
India's Alembic Pharma quarterly profit rises on strong U.S. generics demand
May 15 (Reuters) - Indian drugmaker Alembic Pharmaceuticals posted a 29.2% rise in fourth-quarter profit on Friday, aided by strong demand for its generic drugs and new launches in its key United
Reuters·15 May 26
Cipla Ltd (BOM:500087) Full Year 2026 Earnings Call Highlights: Strong India Growth and ...
Cipla Ltd (BOM:500087) reports robust revenue growth in India and North America, while focusing on AI-driven efficiency and a promising product pipeline.
GuruFocus.com·13 May 26
Indian drugmaker Cipla misses Q4 profit view on weak US sales
May 13 () - Cipla, India's third-largest drugmaker by revenue, reported a weaker-than-expected fourth-quarter profit on Wednesday, dragged by weak sales amid stiff competition in its key U. The drugmaker's consolidated net profit fell 54.
Reuters·13 May 26
Pfizer Just Scored a Win That Wall Street Can't Ignore
The pharmaceutical giant just extended the lifespan of one of its top drugs.
Motley Fool·30 Apr 26
Pfizer (PFE) Reaches Settlement to Extend VYNDAMAX Patent Protection Until 2031
Pfizer Inc. (NYSE:PFE) is one of the most active US stocks to buy right now. On April 28, Pfizer entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals, and Cipla Ltd, resolving patent infringement litigation regarding VYNDAMAX (ta
Insider Monkey·30 Apr 26
Pfizer protects $6.4bn heart disease blockbuster from generics, for now
Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.
Pharmaceutical Technology·29 Apr 26
Pfizer deals extend patent life for a top-selling rare disease drug
Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.
BioPharma Dive·28 Apr 26
Fennec Pharmaceuticals Inc (FENC) Q4 2025 Earnings Call Highlights: Record Sales and Strategic ...
Fennec Pharmaceuticals Inc (FENC) reports a 75% increase in Q4 net product sales, debt-free status, and strategic market expansions amid rising expenses.
GuruFocus.com·24 Mar 26
B Riley Reaffirms Fennec's Buy Rating, US$16.00 Price Target After Cipla Settlement
B. Riley reiterated its buy rating on the shares of Fennec Pharmaceuticals (FRX.TO, FENC) and its US
MT Newswires·17 Mar 26
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Monday afternoon, with the NYSE Health Care Index up 0.8% and the State
MT Newswires·16 Mar 26
Sector Peers
Comparing against 4 peers matched by industry: Branded Medicines
| Stock | Zone | Price | Mcap | P/E | P/B | ROE % | ROCE % | D/E | EPS g% | Div Y% | 1Y Ret % | Quality |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CIPLAYOU Cipla Ltd. | Hold | 1,440.10 | ₹1.17T | 30.18 | 3.41 | — | — | — | — | 0.90 | -4.15 | 8/10 |
| SUNPHARMACEUTICALIND Sun Pharmaceutical Industries Ltd. | Buy | 1,862.80 | ₹4.48T | 39.00 | 5.36 | — | — | — | — | 0.86 | 12.10 | 8/10 |
| ZYDUSLIFESCIENCES Zydus Lifesciences Ltd. | Buy | 1,101.40 | ₹1.10T | 21.83 | 4.23 | — | — | — | — | 0.09 | 14.19 | 9/10 |
| GLAXOSMITHKLINEPHARM Glaxosmithkline Pharmaceuticals Ltd. | Hold | 2,354.80 | ₹398B | 38.44 | 17.44 | — | — | — | — | 2.43 | -27.08 | 10/10 |
| AJANTAPHARMA Ajanta Pharma Ltd. | Hold | 3,180.40 | ₹398B | 37.68 | 8.80 | — | — | — | — | 0.88 | 24.03 | 7/10 |
Green = peer is better than you on that metric (lower for valuation, higher for quality/growth). Click any peer to deep-dive.
AI Deep Dive (Claude)
Daily quota: 0 / 5
No AI analysis yet
Click 'Generate' to have Claude write a bull-case / bear-case / verdict-flip analysis using all the data on this page.
Ask Claude about this stock
Discuss CIPLA with AI0/30 today
Ask anything about CIPLA
I have your fundamentals, all 21 rule evaluations, recent analysis, and your decision journal in context.